TY - JOUR T1 - Binding of IP<sub>3</sub> and Adenophostin A to the N-terminal region of the IP<sub>3</sub> Receptor: Thermodynamic Analysis Using Fluorescence Polarization with a Novel IP<sub>3</sub> Receptor Ligand JF - Molecular Pharmacology JO - Mol Pharmacol DO - 10.1124/mol.109.062596 SP - mol.109.062596 AU - Zhao Ding AU - Ana M Rossi AU - Andrew M Riley AU - Taufiq Rahman AU - Barry V.L. Potter AU - Colin W. Taylor Y1 - 2010/01/01 UR - http://molpharm.aspetjournals.org/content/early/2010/03/09/mol.109.062596.abstract N2 - Inositol 1,4,5-trisphosphate receptors (IP3R) are intracellular Ca2+ channels. Their opening is initiated by binding of IP3 to the IP3-binding core (IBC, residues 224-604 of IP3R1) and transmitted to the pore via the suppressor domain (SD, residues 1-223). The major conformational changes leading to IP3R activation occur within the N-terminal (NT, residues 1-604). We therefore developed a high-throughput fluorescence polarization (FP) assay using a newly synthesised analogue of IP3, FITC-IP3, to examine the thermodynamics of IP3 and adenophostin A binding to the NT and IBC. Using both single-channel recording and the FP assay, we demonstrate that FITC-IP3 is a high-affinity, partial agonist of the IP3R. Conventional 3H-IP3 and FP assays provide similar estimates of the KD for both IP3 and adenophostin A in cytosol-like medium at 4°C. They further establish that the isolated IBC retains the ability of full-length IP3R to bind adenophostin A with ~10-fold greater affinity than IP3. By examining the reversible effects of temperature on ligand binding, we established that favourable entropy changes (TΔS) account for the greater affinities of both ligands for the IBC relative to the NT, and for the greater affinity of adenophostin A relative to IP3. The two agonists differ more substantially in the relative contribution of ΔH and TΔS to binding to the IBC relative to the NT. This suggests that different initial binding events drive the IP3R on convergent pathways towards a similar open state.The American Society for Pharmacology and Experimental Therapeutics ER -